USPTO Patent Applications - Therapeutics (A61P)

Compound Emulsion Injection for Nausea and Vomiting

The USPTO published patent application US20260097042A1 for a compound emulsion combining aprepitant and palonosetron hydrochloride for injection. The formulation claims improved stability and enhanced patient adherence in preventing and treating nausea and vomiting. The application was filed on May 30, 2025.

Compositions and Methods for IV Administration of ABDNAZ for Cancer Treatment

USPTO published patent application US20260097013A1 for compositions and methods for intravenous administration of ABDNAZ (2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone) for cancer treatment. The application, filed on 2025-06-11, covers formulations containing autologous whole blood and ABDNAZ for rapid IV infusion. Inventors: Bryan T. Oronsky, Jan Scicinski, and Scott Caroen.

Compounds and Combinations Thereof for Treating Neurological and Psychiatric Conditions

The USPTO published patent application US20260097006A1 by inventor Herriot Tabuteau, filed September 4, 2025, covering compounds and combinations containing dextromethorphan for treating neurological and psychiatric conditions. The application discloses dosage forms and drug delivery systems typically combined with antidepressants such as bupropion. This publication makes the application publicly available for review and potential opposition.

Epoxytiglienone Compounds for Disrupting Gram-negative Bacterial Biofilms

The USPTO has published patent application US20260097011A1 for epoxytiglienone compounds designed to disrupt biofilms comprising Gram-negative bacteria. The application covers methods of dispersing established biofilms through localized administration, including topical or injection delivery, as well as methods for preventing biofilm formation on medical devices. Inventors include David William Thomas, Paul Warren Reddell, Glen Mathew Boyle, and others. The application was filed on December 2, 2025.

CHIMERIC ANTIGEN RECEPTOR SPACERS

The USPTO published Lyell Immunopharma's patent application US20260098075A1 for chimeric antigen receptors (CARs) incorporating immunoglobulin-derived spacers, such as hinge or loop regions, designed to enhance cytokine release compared to CARs with non-Ig-derived spacers. The spacers may be derived from human immunoglobulins (IgAQ1, IgA2, IgD, IgE, IgG1-4, IgM) or non-human sources (e.g., mouse IgG2A), and may be configured as modular constructs combining multiple Ig hinges or fragments thereof. Filed September 8, 2025.

Fluorescent Probe Compounds for Tumor-Targeted Imaging and Synthesis Methods

USPTO published patent application US20260097137A1 by Hebei Medical University for fluorescent probe compounds utilizing a pyrrolo[2,3-d]pyrimidine core structure conjugated to a fluorescent dye for tumor-targeted imaging. The probes demonstrate high affinity and selectivity for tumor cells, rapid clearance from normal tissues, and prolonged retention at tumor sites. The invention enables in vitro and in vivo tracking, receptor affinity studies, and intraoperative navigation applications.

Epigenetic Editing Tool for Targeting Hepatitis B Virus Gene

USPTO published patent application US20260097133A1 for an epigenetic editing tool targeting hepatitis B virus genes, filed by inventors Wenbo Peng, Junzheng Zhao, Shaoshuai Mao, Leilei Wu, Di Sun, Ruimin Lv, Ying Zang, and Junjian Liu on December 4, 2025. The application covers compositions and methods for epigenetic modification of HBV genes for therapeutic use in biomedicine.

GIP/GLP-1 Dual Agonist Formulations for Metabolic and Liver Disorders

The USPTO published patent application US20260097126A1 disclosing pharmaceutical formulations of small molecule GIP/GLP-1 dual receptor agonists for treating metabolic and liver disorders. The application (No. 18995773) was filed on July 18, 2023, by inventors Brian Lian, Geoffrey E. Barker, Maureen Barnes, Brahmachary Enugurthi, and Jake Gonzalez. The formulations include compounds classified under CPC codes A61K 47/548, A61K 9/0019, and others, with therapeutic applications targeting A61P 3/06 (metabolic disorders).

CD19/CD22 CAR T Cell Treatment for High-Risk Pediatric Acute Lymphoblastic Leukemia

The USPTO published patent application US20260097122A1 for CD19/CD22 chimeric antigen receptor (CAR) T-cell products and methods for treating high-risk or relapsed CD19+ or CD22+ haematological malignancies, specifically pediatric acute lymphoblastic leukemia. The application was filed on May 10, 2023, under application number 18862269. Inventors include Martin Pulé, Persis Amrolia, and Sara Ghorashian.

Oncolytic Vaccinia Viruses and Recombinant Viruses and Methods of Use Thereof

The USPTO published patent application US20260097116A1 by ViroMissile, Inc. covering clonal strains of vaccinia virus engineered as oncolytic virus therapies for treating cancer. The application includes claims for recombinant vaccinia viruses with inactivating mutations and heterologous gene products, pharmaceutical compositions, and methods of use for anti-tumor therapy.

Rapid Conjugate Vaccine Manufacturing Method, Inventprise

Rapid Conjugate Vaccine Manufacturing Method, Inventprise

SNIPR Biome ApS - Treating and Preventing Microbial Infections

USPTO published patent application US20260098259A1 assigned to SNIPR Biome ApS, covering methods for treating microbial infections including acute conditions such as sepsis, septicemia, SIRS, and septic shock. The application also discloses methods for controlling microbiologically influenced corrosion (MIC) and biofouling in industrial or domestic systems.

Enterin Patents Novel Aminosterol ENT-03 Compounds and Compositions

The USPTO published patent application US20260098052A1 for Enterin, Inc., covering novel aminosterol ENT-03 compounds, compositions comprising the same, and methods of making and using the same. The inventors are Denise Barbut and Michael Zasloff. The application was filed December 10, 2025, under application number 19415736. The CPC classifications indicate therapeutic applications including nervous system conditions (A61P 25/00).

Silicon Nanoparticle Delivery System for Controlled Release of Nucleic Acids Including siRNA and mRNA

The USPTO published patent application US20260096997A1 assigned to SISAF LIMITED, filed November 6, 2025. The application covers a composition for controlled release of nucleic acids such as short interfering RNA (siRNA) or messenger RNA (mRNA), comprising silicon nanoparticles comprising at least 50% by weight silicon, at least one amino acid, and at least one lipid. The CPC classifications indicate primary focus on pharmaceutical preparations (A61K) and therapeutic uses including ophthalmological applications (A61P 27/02).

Liposomal Compositions With Anti-Cancer Agents, Tumor-Targeting Lipopeptides

The USPTO published patent application US20260096988A1 on April 9, 2026, filed by inventors Debabrata Mukhopadhyay, Vijay S. Madamsetty, and Krishnendu Pal. The application covers liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides, as well as nanodiamond complexes and particles as carriers for anti-cancer agents. This publication provides public notice of the intellectual property claims related to advanced drug delivery compositions for cancer treatment. The pharmaceutical and biotechnology industries should monitor this application for potential impacts on cancer therapeutics development.

Ether Lipids Hyperactivate Dendritic Cells - Corner Therapeutics

The USPTO published patent application US20260097111A1 by Corner Therapeutics, Inc. on April 9, 2026, covering ether lipid (ETL) and ether phospholipid (ETPL) compounds for hyperactivating mammalian dendritic cells, including compositions combined with pathogen recognition receptor agonists, antigens, and dendritic cells. The application was originally filed on October 18, 2023.

Parsnip Extract Composition for Intestinal Health and Leaky Gut Treatment

USPTO published patent application US20260097089A1 for a composition containing parsnip extract as an active ingredient. The composition is designed to reduce tight junction protein downregulation, promote beneficial intestinal bacteria proliferation, maintain acidic intestinal environment, and reduce intestinal permeability. The application indicates the composition may be used in foods, feeds, pharmaceuticals, or quasi-drugs for improving intestinal health and preventing or treating leaky gut syndrome, obesity, or metabolic diseases.

Herbal Medicine Extracts RM01 for Alzheimer's Treatment

The USPTO has published patent application US20260097090A1, filed September 26, 2023, and published April 9, 2026, covering herbal extract compositions for treating neurodegenerative diseases including Alzheimer's disease. The composition includes extracts from Ophiopogon japonicus, Barbary Wolfberry, Rhizoma Acori tatarinowii, and Codonopsis pilosula. This is a patent application publication, not a granted patent, and does not confer any regulatory approval for the claimed treatments.

Modified oHSV with HRG for Cancer Therapy

The USPTO published patent application US20260097088A1 for a modified oncolytic herpes simplex virus (oHSV) engineered with an expression cassette encoding histidine-rich glycoprotein (HRG) for use in cancer therapy. The invention, filed on August 17, 2023 (Application No. 19113359), leverages virotherapy to selectively target and lyse cancer cells while sparing normal cells. The inventors are Chun-Yu Chen, Pin-Yi Wang, and Timothy P. Cripe.

Cancer Treatment Using Thyroid Hormone Analogs T2 and RT3

USPTO published patent application US20260097100A1 filed by Keith Roger Latham and Regina L. Garland on September 25, 2025, covering methods and compositions for treating cancer through induction of tumor cell differentiation using thyroid hormone analogs such as T2 and RT3. The application discloses pharmaceutical compositions including topical formulations for skin cancer and delivery systems for systemic administration.

Peptide Analogue for Treatment of Diabetes or Obesity

USPTO published patent application US20260097101A1 for a peptide analogue of pancreatic polypeptide (PP) intended for treating diabetes or obesity. Filed September 6, 2023 under application number 19110570, the invention also covers methods of treatment and use in manufacturing a medicament for these conditions.

Methods for Treating Fatty Liver Disease (NASH) with Resmetirom

USPTO published patent application US20260097039A1 disclosing methods of treating fatty liver disease (non-alcoholic steatohepatitis/NASH) and improving liver fibrosis using resmetirom (2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile) or its pharmaceutical salts. Inventors: Rebecca Taub and Dominic Labriola. Application filed December 10, 2025, and published April 9, 2026. This is a publication of a patent application, not a granted patent.

Reboxetine Patent Application for Narcolepsy and Cataplexy Treatment

USPTO published patent application US20260097040A1 by Herriot Tabuteau covering methods of treating narcolepsy with cataplexy using reboxetine or esreboxetine. The application includes pharmaceutical compositions and instructions for use in treating the condition. Filing date was December 11, 2025, with publication on April 9, 2026.

Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells

USPTO published patent application US20260097131A1 titled 'Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells.' The application (filed December 11, 2025) discloses compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo using non-viral delivery of polynucleotides encoding transcription factors. The patent application is now publicly available.

ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF

The USPTO published patent application US20260098078A1 covering activin receptor type II chimera polypeptides for treating conditions involving muscle weakness and atrophy, bone damage, blood disorders such as anemia, thrombocytopenia, and neutropenia, as well as fibrosis, metabolic disorders, and pulmonary hypertension. The application describes extracellular ActRII chimeras optionally fused to Fc domains as therapeutic agents.

Cancer Treatment Patent Using Quinoline Derivative and Antibody

The USPTO published patent application US20260097030A1 on April 9, 2026, disclosing a therapeutic combination of a quinoline derivative and an antibody for treating cancer, specifically lung and liver tumors. The application names 14 inventors and was filed on April 11, 2025. This publication makes the application publicly available but does not grant any enforceable patent rights.

MPN Treatment Methods with Therapeutic Compounds

USPTO published patent application US20260097028A1 for therapeutic methods treating myeloproliferative neoplasms (MPN) including polycythemia vera, essential thrombocythemia, and myelofibrosis. The application covers combination therapies using compounds of Formula (I) or Formula (II) with JAK inhibitors, IDH inhibitors, PD-1/PD-L1/PD-L2 inhibitors, interferons, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, or nucleoside analogs. Filed February 18, 2025, application number 19055807.

Proton Pump Inhibitors for Inhibition of Aortic Valve Calcification

USPTO published patent application US20260097026A1 for the use of proton pump inhibitors including prazole compounds to inhibit calcification of aortic valves, treating aortic sclerosis and stenosis. The application was filed on October 3, 2023, with inventors Arsenii Zabirnyk, Ingvar Jarle Vaage, and Kåre-Olav Stensløkken. The invention is classified under CPC codes A61K 31/4439 and A61P 9/10.

Plant-Based DHA and Berberine Compositions for Treating Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease

The USPTO published patent application US20260097024A1, filed October 7, 2025, covering compositions and methods for treating obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease using synergistically effective amounts of plant-based DHA and berberine. Inventors are Roger Catarino and William Kuhne. The application has been made publicly available as part of the 18-month patent publication process.

Neuroplasticity Treatment Method with Neurostimulation and Dopamine Agonist for Depression

USPTO published patent application US20260097224A1 disclosing a method for treating neuroplasticity-related conditions by administering a dopamine receptor agonist combined with neuroplasticity-modulating drugs prior to or simultaneously with targeted energy-based neurostimulation, repeated within one day. The preferred embodiment targets depression using transcranial magnetic stimulation. Inventors are Donald A. Vaughn and Jonathan A.S. Downar, with application number 19274159 filed July 18, 2025.

Modified-Release Minoxidil Compositions and Methods for Hair Loss Treatment

The USPTO published patent application US20260097035A1 filed by inventor Reid Waldman on December 10, 2025, covering modified-release minoxidil compositions for treating hair loss. The application discloses pharmaceutical formulations for oral administration of modified-release minoxidil and methods of using the compositions for hair loss treatment.

Ypsomed AG Injection Device with Improved Conveying Element Patent Application

The European Patent Office published patent application EP4159257A1 for an injection device with improved conveying element, filed by Ypsomed AG. The application lists six inventors and covers IPC classifications A61M 5/20, A61M 5/24, and A61M 5/315 relating to injection mechanisms. The application is designated for validation in 28 European member states including Germany, France, the United Kingdom, Italy, and Spain.

mRNA, Protein Vaccine Compositions for Influenza

The USPTO published patent application US20260097112A1 by inventors Jacob Glanville et al. covering vaccine compositions comprising combinations of influenza antigens. The application discloses mRNA/LNP, recombinant protein, virus-like particle (VLP), and DNA vaccine formulations. Filing date was October 17, 2025.

Atovaquone Patent, Mast Cell Inflammatory Disease Treatment

Atovaquone Patent, Mast Cell Inflammatory Disease Treatment

Anti-TMPRSS6 Monoclonal Antibodies and Therapeutic Uses

USPTO published patent application US20260098084A1 disclosing fully human anti-TMPRSS6 monoclonal antibodies for treating diseases associated with TMPRSS6. Inventors include Harvey Chin, Sarah J. Hatsell, Heinrich Emil Lob, Andrew J. Murphy, William Olson, Kei Saotome, and Bojie Zhang, with application number 19323318 filed September 9, 2025.

PD-1 Monoclonal Antibody Patent Application for Cancer Treatment

The USPTO published patent application US20260098092A1 for monoclonal antibodies targeting human programmed cell death protein 1 (PD-1) and methods for treating cancer using said antibodies and antigen-binding fragments. The application was filed October 4, 2023, naming seven inventors including Trairak Pisitkun and colleagues. Pharmaceutical and biotech companies developing PD-1/PD-L1 pathway cancer immunotherapies should monitor for this application's progression to grant.

Novel Anti-Asporin Antibody Targets Fibrotic Disease Including Idiopathic Pulmonary Fibrosis

USPTO published patent application US20260098083A1 disclosing a novel antibody binding specifically to Asporin protein for predicting onset and treating fibrotic diseases, including idiopathic pulmonary fibrosis. Inventors are Hogeun Yoon and Soo-Yeon Park. The application was filed on September 20, 2023.

Immunogenic Compositions for SARS-CoV-2 Vaccines Using MHC Class II Peptides

USPTO published patent application US20260097115A1 for immunogenic compositions containing MHC class II-binding peptides derived from SARS-CoV-2 translation products. The application covers vaccine compositions and methods for treating and preventing COVID-19. Inventors include researchers from Broad Institute and affiliated institutions.

Anti-C5 Antibody, C5 iRNA Dosing Regimens, Complement Diseases

Anti-C5 Antibody, C5 iRNA Dosing Regimens, Complement Diseases

CCR8 Antibodies and Fusion Proteins for Cancer Treatment

The USPTO published patent application US20260098098A1 covering CCR8-binding antibodies and fusion proteins for cancer treatment. Inventors McGrath et al. filed Application No. 19182473 on April 17, 2025, with the application published on April 9, 2026. The patent covers therapeutic compositions and methods using CCR8-targeted biologics.

Immunotoxin-Based Targeted Therapy for Cancer, CCR4 Bispecific

The USPTO published patent application US20260098097A1 for methods of treating cancer using a genetically engineered C-C motif chemokine receptor 4 (CCR4) bispecific immunotoxin. The application, filed December 29, 2023, covers treatment of cutaneous T-cell lymphoma and other cancers via administration of the immunotoxin alone or in combination with additional therapeutic agents such as antibody-drug conjugates.

Anti-CCR8 Antibodies Therapeutic Agents Patent Application

USPTO published patent application US20260098096A1 for anti-CCR8 antigen binding proteins and fragments for detection and therapy of various conditions, including cancer. The application was filed September 21, 2023, by inventor Remy Michel Robert. CCR8 is a G-protein coupled receptor implicated in tumor immunosuppression.

Multispecific Antibodies Targeting HLA-A2/MAGE-A4 Cancer Therapy

USPTO published Roche/Genentech patent application US20260098095A1 disclosing multispecific antibodies binding to HLA-A2/MAGE-A4 complex for T cell activation in cancer treatment. The application covers antibody compositions, encoding polynucleotides, production methods, and therapeutic uses. The invention addresses immunotherapy approaches for HLA-A2-positive tumors expressing MAGE-A4 antigen.

US20260098093A1, VISTA Molecules, Cancer Treatment, 9th Apr

US20260098093A1, VISTA Molecules, Cancer Treatment, 9th Apr

Painless NGF Compositions for Fracture Repair

The USPTO published patent application US20260097099A1 for painless nerve growth factor (NGF) compositions for bone fracture repair, filed by inventors Chelsea Bahney, Tejal Desai, Kevin Rivera, and Chengbiao Wu. The application covers pharmaceutical compositions comprising biomaterial carriers with painless NGF for stimulating bone fracture healing. Filing date was April 23, 2025.

4-1BBL AND IL-12 COMBINATION THERAPY FOR GLIOBLASTOMA

The USPTO published patent application US20260097096A1, a new intellectual property grant covering methods of treating glioblastoma using 4-1BBL administered via adeno-associated virus (AAV-F) in combination with recombinant IL-12 delivered by intratumoral injection. The patent names Koen Breyne, Xandra O. Breakefield, and Thorsten R. Mempel as inventors. Biotech and pharmaceutical companies developing cancer immunotherapies must monitor this IP landscape.

Pegylated Lipoprotein Nanoparticles Treat Neurodegenerative Diseases

The USPTO published patent application US20260097095A1 for pegylated reconstituted high-density lipoprotein nanoparticles designed to prevent or treat neurodegenerative diseases. The application, filed by inventors Lee, Kim, and Kim on October 10, 2025, was published on April 9, 2026.

DBI Protein Modulation Methods for Autophagy and Metabolic Regulation

The USPTO published patent application US20260097094A1 disclosing methods for modulating diazepam binding inhibitor (DBI) protein activity to regulate autophagy and metabolic processes. The inventors demonstrate that DBI neutralization via monoclonal antibodies or active immunization induces autophagy, enhances starvation-induced weight loss, reduces food intake upon refeeding, and reduces weight gain from hypercaloric diets. The patent covers pharmaceutical compositions and therapeutic applications for metabolic disorders.

Targeted Amatoxin Conjugate for Treatment of Solid Tumors

Heidelberg Pharma Research GmbH has published a US patent application (US20260097093A1) for a targeted amatoxin-linker conjugate designed to treat solid tumors. The application discloses an amatoxin-linker construct where R1 and R2 are each OH, R3 is NH2 or a linker, R4 is H or a linker, and R5 is absent or O, with the conjugate useful in manufacturing binding moiety-toxin therapeutics. Filing date was October 6, 2025.

Pharmaceutical Composition Containing Mitochondria-Targeting Compound for Treating Macular Degeneration

The USPTO published patent application US20260097092A1 filed by Ulsan National Institute of Science and Technology for a pharmaceutical composition containing mitochondria-targeting compounds as active ingredients for treating macular degeneration and other retinal diseases. The application specifically covers compounds that induce apoptosis of senescent cells for prevention and treatment of aging-related diseases. The application was originally filed on January 11, 2023.